Renal Mechanism of Action/Splay vs. TmG

Part of paid clinical trials in San Antonio, Texas.

Sponsor: AstraZeneca
Study ID: NCT00726505
Phase: PHASE1
Status: Terminated

Conditions

Diabetes, NOS

Eligibility Criteria

Sex: ALL
Age: 18 Years - 65 Years
Healthy Volunteers: Accepted

Interventions

Dapagliflozin — DRUG
Tablets, Oral, Once Daily, up to 29 days:

Study Details

The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus

Key Dates

Start date: Jun 30, 2009
Status verified: Oct 2016
Primary completion: Aug 31, 2009
Completion: Aug 31, 2009

Study Design

Enrollment: 1 participants (actual)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Arms

Active Comparator: Group 1
Subjects with T2DM - Dapagliflozin 5 mg
Active Comparator: Group 2
Subjects with T2DM - Dapagliflozin 20 mg
Active Comparator: Group 3
Healthy Subjects - Dapagliflozin 20 mg

Primary Outcome Measure

The change in urinary glucose excretion dynamics [ Time Frame: after 7 days of treatment ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
University Of Texas Health Center At San Antonio	San Antonio	Texas	78229	-

Find similar trials in San Antonio, TX

By research site

University Of Texas Health Center At San Antonio· San Antonio, TX